• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169673 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
- {6 J: P9 S! N) V; C5 o9 a" ?: f: f+ ~% L( ]4 l

# m: z# S9 H& [/ P: i+ dSub-category:
# c  o; R8 A  ^6 P' dMolecular Targets
0 `- c% M' h. A* o. g8 J' [5 i% U, ^/ P+ V& Q) F" m
. e8 e( f% ?9 w1 G" E. e
Category:
6 h- K: ?3 J- Y$ M; N6 X$ ?  VTumor Biology ) ~3 j- E9 r  Y# L
! o# }+ F  `; e2 R

/ d5 U0 V0 k2 U8 UMeeting:
2 i6 Y9 D/ N: G: j6 C& h4 t2011 ASCO Annual Meeting
) \1 j1 A" S! G1 {
% \0 Z1 d# O& G: {! h3 f# O# g3 `
Session Type and Session Title:4 \" W6 O+ c* E4 f  j0 R
Poster Discussion Session, Tumor Biology
* {* V+ H6 ~7 D! C" n/ a( }- w; R2 W7 c/ O% W
  b3 }$ e% g* d1 S( U; u
Abstract No:
0 L4 N* n+ U; v( W% x" f. w: p10517
8 d! h8 f3 T3 v4 A" \7 n0 p  \, W, P
) L; `1 o- K8 U
; j6 ^' M, f/ J7 \Citation:, k+ S: Z; W# s/ r/ I
J Clin Oncol 29: 2011 (suppl; abstr 10517) : o- C6 s0 t8 }, v0 Q- ~2 \: E

! V' Z( a* `' F6 T6 S; G3 b& P/ S: j" j" H: Z8 P9 W- j* ?
Author(s):
  {# d8 m% _( c* l: GJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
9 u! }' Q$ u7 q/ [" L. Y; n/ k3 D( y
6 U. C& {4 n6 H( k4 o- v# \) B
7 s# B  D" H2 q, r* x2 y
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
5 B& `2 o/ _+ D* @
  a" L* z( D3 ^( [; L* X. zAbstract Disclosures: P- Z3 _3 D0 W' i9 W. J1 b

9 v6 L- ]5 t: q& \) zAbstract:
) z+ A$ D& |1 m1 W* |* \& K2 W2 S& u- ]5 w$ R. U: O: R9 x
1 c- S! m& ~+ N$ H& r: P8 j1 b
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.. n$ K) ?" a8 j% T# c4 ]6 U
* I7 f1 u7 s( P4 K8 W

, N& V1 J  h! ~0 r
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 # @) l1 H- i; l% p/ ?
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

/ a8 f* v& x1 b: s0 K* l化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
% W+ X  V. R! w" b易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
* t8 p9 R( O, n. e4 \ALK一个指标医院要900多 ...
% U, v: ]: \7 o- u
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
+ D; P% a. a& `  f# f% ?8 P7 Z0 E$ T# m. B4 U5 r
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表